Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what's important in pharma and biotech. Each weekday it condenses key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences. The show is produced by OWITH.ai, a boutique AI & data studio.
Episodes
Roche's Divarasib Surpasses Amgen in Trials | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care.
Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising res
Orca Bio's Tregzi Wins FDA Approval for GVHD | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry.
Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel trea
FDA Fast-Tracks Eli Lilly & Regeneron | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape.
To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, F
Ipsen Buys Kartos for $1.75B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, where significant scientific advancements, regulatory shifts, and strategic business maneuvers are reshaping patient care and therapeutic approaches.
A pivotal moment recently unfo
Replimune's RP1 Resubmission to FDA: Will It Finally Pass? | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry.
Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treatin
Merck's $11.3B Bio-Techne Acquisition | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements.
Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck’s most s
Eli Lilly's $1.9B Abbisko Partnership Boosts Cancer R&D | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, a
Carsgen's $2T Satricabtagene Approval Milestone | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the latest scientific breakthroughs, regulatory advancements, and strategic industry movements that are shaping the landscape of healthcare innovation.
Kicking off with significant strides in drug approvals, Carsgen Therapeutics has ma
Carsgen's CAR-T Breakthrough in China for Solid Tumors | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare.
In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This th
FDA Approves Alzheimer's Drug Amid Debate | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now.
Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a r
FDA Approves Utebzi, Biogen Acquires Raythera for $1B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology.
In the realm of oncology, min
Eli Lilly's $65B M&A Surge & FDA's Drug Import Approval | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers.
The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in
Intellia's 89% Success in Phase 3 CRISPR Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape.
Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for h
Novartis' $23M RNA Breakthrough & Tavneos FDA Battle | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution.
Novartis has made headlines with its investi
Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies.
Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Mye
Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways.
Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare.
In a significant scientific breakthrough, Merck & Co. and Gilead Sciences h
Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care.
Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a
Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligen
Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strat
Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly.
Starting wit
Moderna-Merck Combo Cuts Melanoma Risk by 49% | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care.
In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b t
Akeso's Ivonescimab Shows 34% Death Risk Cut at ASCO | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development.
At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneer
Pfizer's $10B Innovent Deal Boosts Cancer Drugs | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development.
Pfizer's monumental $10 billion col
Eli Lilly's Zepbound Coverage Restored! Breaking News | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across t
Outlook Therapeutics Wins FDA Appeal for $1.3B Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs.
A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab),
Gilead's Hepcludex FDA Approval Marks Milestone | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care.
One of the noteworthy developments is the U.S. FDA's recent a
Lilly's Obesity Drug Rivals Surgery: FDA Changes Ahead | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, a domain experiencing profound changes marked by leadership transitions, regulatory challenges, and groundbreaking scientific advancements.
Recent developments within the FDA highl
AstraZeneca's Datroway FDA Approved for TNBC | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care.
Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured F
Eli Lilly's $1B Novo Nordisk Deal: Diabetes Focus | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest updates from the ever-evolving landscape of pharmaceuticals and biotechnology, where innovation is as much a constant as the challenges these industries face.
Recently, Fierce Biotech Week in Boston highlighted a shift toward
Pfizer Leads Pneumococcal Vaccine Efforts | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of exciting advancements and strategic moves that are shaping the future of healthcare.
Let's start with Pfizer's efforts in pneumococcal vaccination, a testament to the ongoing battle against Streptococcus pneumoniae.
Takeda Faces $885M Verdict in Antitrust Case | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest happenings shaping the landscape of this dynamic industry.
The pharmaceutical and biotech sectors are navigating a complex landscape replete with scientific advancements and regulatory challenges. A significant legal development comes
Regeneron $2.3B Deal & FDA Shake-Up | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results.
A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from
Eisai's Leqembi Forecasts $900M Sales Boost | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of transformative events shaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic realignments.
Eisai's progress with its Alzheimer's treatment, Leqembi, marks a significant milestone in ad
Beone's Beqalzi FDA Approval Challenges AbbVie | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery.
Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commis
Takeda Lays Off 4,500 | FDA Leadership Change News | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the dynamic shifts and breakthroughs shaping this ever-evolving industry.
In a significant regulatory update, the resignation of FDA Commissioner Marty Makary has stirred discussions across the pharmaceutical landscape. Over his 13-mont
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant shifts and advancements shaping our industry.
Kicking off with a notable change in leadership, the resignation of FDA Commissioner Marty Makary signals an important realignment within the U.S. regulatory landscap
Daiichi Sankyo's $1.3B Oncology Plan & CSL's $5B Setback | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories and trends shaping the industry.
Daiichi Sankyo has unveiled a bold five-year business plan with an eye on rising to become a top-five global oncology leader by 2035. This ambition is driven by a $1.3
Gilead Projects $1B YezTugo Sales | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into a range of significant industry updates, spotlighting scientific advancements, regulatory challenges, and strategic movements that are shaping the future of drug development and patient care. The pharmaceutical landscape is often mark
Roche Acquires PathAI for $1B: AI-Driven Diagnostics Revolution | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
In a rapidly evolving industry landscape, artificial intelligence has emerged as a game-changer, transforming how major pharmaceutical companies approach drug development and diagnostics. Roche's strategic acquisition of PathAI for over $1 billion exemplifies t
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
The industry is buzzing with significant shifts driven by scientific advancements, strategic acquisitions, and regulatory changes. A noteworthy transaction is Bayer's $2.4 billion acquisition of Perfuse, aimed at gaining control over an eye disease implant that
Sanofi Invests $294M in AI, FDA Approves Auvelity | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which are experiencing significant transformations driven by scientific advancements, strategic realignments, and regulatory changes.
Sanofi is making a s
Pfizer's $300M Biologics Boost & FDA's Veppanu Approval | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant updates that highlight the dynamic nature of our industry, driven by cutting-edge science, regulatory evolution, and strategic business innovations.
The pharmaceutical landscape is ever-shifting, with recent deve
AstraZeneca's $5B Setback: FDA Rejects New Cancer Drug | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative dynamics shaping the industry, from financial innovations to regulatory hurdles, each having profound implications for patients and stakeholders alike.
The pharmaceutical and biotech industries are in the midst of a transforma
Novartis' $23B U.S. Investment Boosts Pharma Manufacturing | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of significant advancements, strategic investments, and regulatory updates reshaping the landscape of drug development and patient care.
In a remarkable move, Novartis has announced a $23 billion investment in the U.S., with pl
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into an array of dynamic changes and strategic maneuvers within the industry, showcasing how these transformations are shaping the future of healthcare and patient treatment.
Starting with regulatory innovation, the FDA's new initiative to facil
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve rapidly with significant developments in drug approvals, regulatory changes, and innovative therapies. The latest updates highlight the tension between scientific advancement and regulatory scrutiny.
A prime example is the FDA's
Sun Pharma's $11.75B Organon Deal: Industry Shockwave | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care.
Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the
Merck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry.
At the latest meeting of the American Association for Cancer Research, innovative cancer therapies were in the spotlight. Merck showcased it
Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Regeneron has recently achieved a pivotal milestone with the FDA's approval of its hearing loss gene therapy, Otarmeni. This approval, facilitated through the FDA’s Commissioner's National Priority Voucher Program, emphasizes the expanding recognition of g
Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal events shaping the industry.
Starting with Amneal Pharmaceuticals' strategic acquisition of Kashiv Biosciences for $1.1 billion, this move highlights what many are calling the "golden era" for biosimil
Merck Welireg Fails, Roche Enspryng Shines in Trials | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care.
In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatmen
Eli Lilly's $7B Kelonia Buy Boosts CAR-T Tech | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic moves that are reshaping the landscape of drug development and patient care.
In vaccine development, Sanofi has recently reported promising results from a comparative trial of its protein-b
Kailera IPO Raises $625M for Obesity Drug | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthet
Gene Therapy Setbacks and Strategic Shifts in Biotech
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. This week, we delve into a series of compelling stories that are shaping the future of drug development, therapeutic innovation, and patient care.
The gene therapy sector is currently under the spotlight, with Johnson & Johnson handing back the rights to botaret
AI Integration and Regulatory Shifts in Pharma
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a fascinating realm where technology and biology converge, starting with a deepening relationship between biopharma and artificial intelligence.
Novartis CEO Vas Narasimhan's recent appointment to the board of AI company Anthropic si
AI Integration, FDA Milestones, and Strategic Shifts: Navigating Pharma's Future
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative updates that reflect the dynamic landscape of our industry.
Johnson & Johnson is making strategic moves in the immunology space, with Tremfya and the newly launched Icotyde playing pivotal roles in their portfolio.
Radiopharmaceuticals to CAR-T: Pharma's Cutting-Edge Advances
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most intriguing advancements and strategic moves shaping the future of drug development and patient care.
Regeneron has recently ventured into the radiopharmaceuticals market through a substantial $2.1 billion agreement with Australi
Biopunk Revolution: Reshaping Biotech Innovation
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the transformative potential of biopunk and community labs that are reshaping the biotechnology landscape. The biopunk movement, inspired by the punk music ethos, advocates for a more accessible, nimble, and innovative biotech future thr
Revolutionizing Pharma: Key Innovations and Strategic Shifts
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of exciting and transformative updates shaping our industry.
Let’s begin with the departure of a significant figure in pharmaceutical advocacy. Steven Ubl's exit as CEO of PhRMA marks a noteworthy change after over a decad
Navigating Breakthroughs: Pharma's Evolution in Innovation and Strategy
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of dynamic changes and strategic shifts reshaping these industries, driven by scientific advancements and regulatory updates.
Let's start with Biogen, which recently resolved an investor lawsuit concerning its Alzheimer's drug
FDA's New Agenda & Gilead's Oncology Leap
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic moves shaping the ever-evolving landscape of drug development and patient care.
The U.S. Food and Drug Administration, under Commissioner Marty Makary, is pursuing a comprehensive polic
Pharma's Future: Mergers, Innovation, and AI
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events reshaping the industry as we know it.
The pharmaceutical and biotech sectors are currently experiencing an unprecedented surge in mergers and acquisitions. This wave of consolidation is exemplified by Neurocrine
Navigating Biopharma's Strategic Shift: Key Developments
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the key changes shaping our industry, from a contraction in drug development pipelines to shifts in international trade policies, and what these might mean for the future of healthcare.
Recent reports from Citeline indicate that for the
